EyePoint's Phase 3 failure; Lilly's China drug delivery deal

Phase 3negativeRyzumviNegative

AI Analysis

Summary

EyePoint, a Watertown, MA-based biotech, is cutting 53% of its positions after its experimental drug failed in a Phase 3 trial. The newsletter also notes a Lilly drug delivery deal in China, Longwood's next fund, and a Ryzumvi label expansion.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

EyePoint's experimental drug failed in a Phase 3 trial; the company is cutting 53% of its positions. Drug name and trial details not provided in the excerpt.

Importance:7/10

Sentiment:

-0.70

Phase 3 failurelayoffsrestructuringdrug deliverylicensing deallabel expansionventure fund

Related Companies

$LLY

Read the original article

Published by Endpoints News on October 19, 2026 3:01 PM

Read Original